Prolonged improvement of Raynaud's phenomenon and scleroderma after recombinant tissue plasminogen activator therapy.
We describe a patient with systemic sclerosis (SSc; scleroderma) characterized by severe Raynaud's phenomenon, cutaneous sclerosis, and digital ulceration and subsequent amputation who was treated with recombinant tissue plasminogen activator (rt-PA) after acute myocardial infarction. She showed prompt improvement of the Raynaud's phenomenon and healing of the digital ulceration. After 18 months of followup, the Raynaud's phenomenon has remained mild, and there has been improvement in the cutaneous sclerosis. Since the pathophysiology of SSc has been associated with disorders of fibrinolysis and coagulation, this patient represents an interesting index case that might prompt further evaluation of rt-PA therapy in carefully selected patients.
Fritzler
M J
MJ
Faculty of Medicine, Department of Medicine, University of Calgary, Alberta, Canada.
Hart
D A
DA
D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D009203:Myocardial Infarction / Q000188:drug therapy; D011928:Raynaud Disease / Q000188:drug therapy*; D012594:Scleroderma, Localized / Q000188:drug therapy; D012595:Scleroderma, Systemic / Q000188:drug therapy*; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*
D010959:Tissue Plasminogen Activator